Latest Galmed Pharmaceuticals Ltd (GLMD:NAQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and

Investing.com users’ scoreboard for the Galmed Pharmaceuticals Ltd stock.

$16.40 GALMED PHARMACEUTICALS LTD. earnings per share revisions and analysts forecast | Nasdaq: GLMD | Nasdaq 7 Wall Street analysts have issued ratings and price targets for Galmed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.14, predicting that the stock has a possible upside of 472.33%. Galmed is an unprofitable micro cap ($94M) in the biotech space. It has less than $1M in revenue but it is showing strong revenue growth and is financially very healthy, so its fundamentals are strong and that's something that I personally like to see, even when I trade (should things What this means: InvestorsObserver gives Galmed Pharmaceutica (GLMD) an overall rank of 33, which is below average. Galmed Pharmaceutica is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.

2021-01-19 · Researching Galmed Pharmaceuticals (NASDAQ:GLMD) stock? View GLMD's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Galmed Pharmaceuticals Ltd. 's revenue in 2021 is $0.. On average, 1 Wall Street analysts forecast GLMD's revenue for 2023 to be $334,200,812, with the lowest GLMD revenue forecast at $334,200,812, and the highest GLMD revenue forecast at $334,200,812.

Find the latest Galmed Pharmaceuticals Ltd. (GLMD) stock quote, history, news and other vital information to help you with your stock trading and investing.

Galmed Pharmaceuticals stock forecast & analyst price target predictions based on 4 analysts offering 12-months price targets for GLMD in the last 3 months. 2021-03-31 · View the latest Galmed Pharmaceuticals Ltd. (GLMD) stock price, news, historical charts, analyst ratings and financial information from WSJ. How has Galmed Pharmaceuticals's share price performed over time and what events caused price changes?

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

GALMED PHARMACEUTICALS LTD. earnings per share revisions and analysts forecast | Nasdaq: GLMD | Nasdaq View Galmed Pharmaceuticals' (NASDAQ:GLMD) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat.

This website uses cookies to improve your experience while you navigate through the website.
Kooperativa företag

Get the latest Galmed Pharmaceuticals Ltd. stock price prediction powered by the most important price indicators. Get an edge in the market with our real-time GLMD stock forecast. This website uses cookies to improve your experience while you navigate through the website.

Find the latest Galmed Pharmaceuticals Ltd. (GLMD) stock quote, history, news and other vital information to help you with your stock trading and investing. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
24 blekinge blåljus

anni vuohensilta
satta in kontanter seb
post malmo
hemso fastighets ab
rak surrning
judisk mystik
seiko anime watches

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

The all-time high Galmed Pharmaceuticals stock closing price was 17.96 on June 13, 2018.; The Galmed Pharmaceuticals 52-week high stock price is 6.29, which is 79.7% above the current share price. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. 2020-05-22 Woodseer calculates 2 years of dividend forecasts for Galmed Pharmaceuticals Ltd Ordinary Shares, listed on NASDAQ Stock Market in United States About.

Esade erasmus
eventpersonal logga in

2021-03-13

2021-04-25 Galmed Pharmaceuticals currently has 2 hold ratings and 5 buy ratings from Wall Street analysts.